BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1154@pharmaconomics
DTSTAMP:20260707T051348Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:ASND Phase 2 — TransCon IL-2 β / γ (estimated date)
DESCRIPTION:Phase 2 trial results for TransCon IL-2 β / γ in late-line platinum-resistant ovarian cancer are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1612042/000119312526009636/d13397d6k.htm\n\nTrack it: https://www.pharmaconomics.com/e/1154
URL:https://www.pharmaconomics.com/e/1154
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ASND catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR